Posted in | News | Nanomedicine

Sorrento to Present Data on Cynviloq Nanoparticle Paclitaxel for Ovarian Cancer at AACR Conference

Download PDF Copy

Editorial Checklist

Reviewed

Sep 17 2013

Sorrento Therapeutics, Inc. announced today it will present the clinical data for Cynviloq™ (IG-001), which resulted in its approval as 1^st line treatment of ovarian cancer by Korean FDA in March of 2013.

Highlights of the findings include proof of non-inferiority of Cynviloq vs. Taxol in combination therapy with Carboplatin in patients with advanced epithelial ovarian cancer.

These data will be presented at the AACR conference on Advances in Ovarian Cancer Research: From Concept to Clinic, Miami, FL on Friday, September 20, 2013 12:30 p.m. – 2:30 p.m. at the Met Ballroom 5-7, Poster Session B, Poster Board #B67. The presentation is entitled: “IG-001 — A Non-biologic Nanoparticle Paclitaxel for the Treatment of Ovarian Cancer” authored by: Larn Hwang, Catherine Cheng, and Vuong Trieu.

Source:

http://sorrentotherapeutics.com/

Download PDF Copy

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback

Public Comment

Private Feedback to AZoNano.com

Submit

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.